Abstract Library

#100 Mammalian target of rapamycin (mTOR) expression analysis and therapeutic approach in lung and gastroenteropancreatic poorly differentiated endocrine carcinoma (PDEC)

Introduction: PDEC clinically include gastroenteropancreatic PDEC, small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). These tumors are clinically similar and aggressive and they are usually treated with platinum compounds. mTOR signalling pathway has emerged as a promising target for well-differentiated endocrine carcinoma therapy. Because of varying behavior, PDEC are usually excluded from clinical trials employing the mTOR inhibitor RAD001.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Catena L, Milione M, Pusceddu S, Ducceschi M, Avarino M,

Keywords: poorly differentiated endocrine carcinoma, mTOR, RAD001,

#99 Gene mutations and Hypoxia Inducible Factor (HIF-1) expression as prognostic-predictive factors in pheochromocytomas/paragangliomas (P/P)

Introduction: P/P are rare tumors sporadically associated with familial disorders. In advanced/unresectable disease, no standard treatment has so far been well established. Recently a mutation of some genes (SDHB, SDHC, SDHD) involved in the pathogenesis of familial P/P was discovered. These mutations are often associated with an over-expression of HIF-1, which plays a central role in angiogenesis and cell proliferation. This pathway is known to be inhibited by some targeted therapies, such as sunitinib or sorafenib.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Procopio G, Milione M, Pusceddu S, Valente M, Avarino C,

Keywords: pheochromocytomas, paragangliomas, SDHB mutation, HIF-1, targeted therapies,